Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints

被引:20
作者
Tamhane, Ajit C. [1 ]
Wu, Yi [2 ]
Mehta, Cyrus R. [3 ,4 ]
机构
[1] Northwestern Univ, Dept IEMS, Evanston, IL 60208 USA
[2] Northwestern Univ, Dept Stat, Evanston, IL 60208 USA
[3] Cytel Corp, Cambridge, MA 02139 USA
[4] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02139 USA
关键词
adaptive designs; familywise error rate; gatekeeping procedures; multiple comparisons; O'Brien-Fleming boundary; Pocock boundary; CLINICAL-TRIALS; DESIGN;
D O I
10.1002/sim.5372
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In a previous paper we studied a two-stage group sequential procedure (GSP) for testing primary and secondary endpoints where the primary endpoint serves as a gatekeeper for the secondary endpoint. We assumed a simple setup of a bivariate normal distribution for the two endpoints with the correlation coefficient ? between them being either an unknown nuisance parameter or a known constant. Under the former assumption, we used the least favorable value of ??=?1 to compute the critical boundaries of a conservative GSP. Under the latter assumption, we computed the critical boundaries of an exact GSP. However, neither assumption is very practical. The ??=?1 assumption is too conservative resulting in loss of power, whereas the known ? assumption is never true in practice. In this part I of a two-part paper on adaptive extensions of this two-stage procedure (part II deals with sample size re-estimation), we propose an intermediate approach that uses the sample correlation coefficient r from the first-stage data to adaptively adjust the secondary boundary after accounting for the sampling error in r via an upper confidence limit on ? by using a method due to Berger and Boos. We show via simulation that this approach achieves 511% absolute secondary power gain for ? =0.5. The preferred boundary combination in terms of high primary as well as secondary power is that of O'Brien and Fleming for the primary and of Pocock for the secondary. The proposed approach using this boundary combination achieves 72-84% relative secondary power gain (with respect to the exact GSP that assumes known ?). We give a clinical trial example to illustrate the proposed procedure. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:2027 / 2040
页数:14
相关论文
共 12 条
  • [1] Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation
    Tamhane, Ajit C.
    Wu, Yi
    Mehta, Cyrus R.
    STATISTICS IN MEDICINE, 2012, 31 (19) : 2041 - 2054
  • [2] Testing One Primary and Two Secondary Endpoints in a Two-Stage Group Sequential Trial With Extensions
    Tamhane, Ajit C.
    Xi, Dong
    Mehta, Cyrus R.
    Romanenko, Alexander
    Gou, Jiangtao
    STATISTICS IN MEDICINE, 2025, 44 (3-4)
  • [3] A Bayesian two-stage group sequential scheme for ordinal endpoints
    Zhong, Chengxue
    Miao, Hongyu
    Pan, Haitao
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2023, 72 (03) : 670 - 687
  • [4] Considerations on Testing Secondary Endpoints in Group Sequential Design
    Li, Xiaoming
    Wulfsohn, Michael S.
    Koch, Gary G.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (04): : 333 - 337
  • [5] Estimation of secondary endpoints in two-stage phase II oncology trials
    Kunz, Cornelia Ursula
    Kieser, Meinhard
    STATISTICS IN MEDICINE, 2012, 31 (30) : 4352 - 4368
  • [6] Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance
    Li, Huiling
    Wang, Jianming
    Luo, Xiaolong
    Grechko, Janis
    Jennison, Christopher
    BIOMETRICAL JOURNAL, 2018, 60 (05) : 893 - 902
  • [7] Analysis of innovative two-stage seamless adaptive design with different endpoints and population shift
    Mai, Weijia
    Chow, Shein-Chung
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (06) : 993 - 1006
  • [8] What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials
    Penel, Nicolas
    Ryckewaert, Thomas
    Kramar, Andrew
    BULLETIN DU CANCER, 2014, 101 (04) : E19 - E24
  • [9] Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints
    Sun, Yiming
    Zhang, Xinyi
    Tan, Xianming
    Tu, Dongsheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 105
  • [10] Sample size determination in group-sequential clinical trials with two co-primary endpoints
    Asakura, Koko
    Hamasaki, Toshimitsu
    Sugimoto, Tomoyuki
    Hayashi, Kenichi
    Evans, Scott R.
    Sozu, Takashi
    STATISTICS IN MEDICINE, 2014, 33 (17) : 2897 - 2913